|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR45 |
Gene summary for WDR45 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR45 | Gene ID | 11152 |
| Gene name | WD repeat domain 45 | |
| Gene Alias | JM5 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | A0A024QYX1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11152 | WDR45 | LZE4T | Human | Esophagus | ESCC | 9.17e-11 | 2.51e-01 | 0.0811 |
| 11152 | WDR45 | LZE5T | Human | Esophagus | ESCC | 1.66e-03 | 1.51e-01 | 0.0514 |
| 11152 | WDR45 | LZE7T | Human | Esophagus | ESCC | 5.00e-10 | 5.31e-01 | 0.0667 |
| 11152 | WDR45 | LZE8T | Human | Esophagus | ESCC | 5.44e-11 | 2.18e-01 | 0.067 |
| 11152 | WDR45 | LZE20T | Human | Esophagus | ESCC | 5.94e-08 | 1.73e-01 | 0.0662 |
| 11152 | WDR45 | LZE21D1 | Human | Esophagus | HGIN | 2.33e-02 | 2.01e-01 | 0.0632 |
| 11152 | WDR45 | LZE22D1 | Human | Esophagus | HGIN | 7.20e-03 | 7.18e-02 | 0.0595 |
| 11152 | WDR45 | LZE24T | Human | Esophagus | ESCC | 4.12e-31 | 6.82e-01 | 0.0596 |
| 11152 | WDR45 | LZE21T | Human | Esophagus | ESCC | 1.82e-07 | 1.93e-01 | 0.0655 |
| 11152 | WDR45 | LZE6T | Human | Esophagus | ESCC | 8.83e-08 | 2.11e-01 | 0.0845 |
| 11152 | WDR45 | P1T-E | Human | Esophagus | ESCC | 4.82e-11 | 4.85e-01 | 0.0875 |
| 11152 | WDR45 | P2T-E | Human | Esophagus | ESCC | 2.84e-33 | 7.31e-01 | 0.1177 |
| 11152 | WDR45 | P4T-E | Human | Esophagus | ESCC | 1.78e-33 | 5.62e-01 | 0.1323 |
| 11152 | WDR45 | P5T-E | Human | Esophagus | ESCC | 3.44e-12 | 2.30e-01 | 0.1327 |
| 11152 | WDR45 | P8T-E | Human | Esophagus | ESCC | 1.33e-33 | 5.32e-01 | 0.0889 |
| 11152 | WDR45 | P9T-E | Human | Esophagus | ESCC | 9.89e-30 | 5.92e-01 | 0.1131 |
| 11152 | WDR45 | P10T-E | Human | Esophagus | ESCC | 6.08e-17 | 3.59e-01 | 0.116 |
| 11152 | WDR45 | P11T-E | Human | Esophagus | ESCC | 2.49e-24 | 8.71e-01 | 0.1426 |
| 11152 | WDR45 | P12T-E | Human | Esophagus | ESCC | 1.25e-25 | 3.61e-01 | 0.1122 |
| 11152 | WDR45 | P15T-E | Human | Esophagus | ESCC | 6.13e-19 | 4.41e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00004226 | Breast | Precancer | autophagy of mitochondrion | 14/1080 | 81/18723 | 2.01e-04 | 3.16e-03 | 14 |
| GO:00617266 | Breast | Precancer | mitochondrion disassembly | 14/1080 | 81/18723 | 2.01e-04 | 3.16e-03 | 14 |
| GO:00316679 | Breast | Precancer | response to nutrient levels | 47/1080 | 474/18723 | 2.09e-04 | 3.27e-03 | 47 |
| GO:00224119 | Breast | Precancer | cellular component disassembly | 44/1080 | 443/18723 | 3.17e-04 | 4.51e-03 | 44 |
| GO:00714969 | Breast | Precancer | cellular response to external stimulus | 33/1080 | 320/18723 | 9.01e-04 | 1.03e-02 | 33 |
| GO:00316688 | Breast | Precancer | cellular response to extracellular stimulus | 27/1080 | 246/18723 | 1.02e-03 | 1.13e-02 | 27 |
| GO:00092677 | Breast | Precancer | cellular response to starvation | 19/1080 | 156/18723 | 1.65e-03 | 1.67e-02 | 19 |
| GO:00425947 | Breast | Precancer | response to starvation | 22/1080 | 197/18723 | 2.30e-03 | 2.15e-02 | 22 |
| GO:19030085 | Breast | Precancer | organelle disassembly | 15/1080 | 114/18723 | 2.31e-03 | 2.15e-02 | 15 |
| GO:00316697 | Breast | Precancer | cellular response to nutrient levels | 22/1080 | 215/18723 | 6.58e-03 | 4.53e-02 | 22 |
| GO:003166714 | Breast | IDC | response to nutrient levels | 62/1434 | 474/18723 | 2.33e-05 | 5.57e-04 | 62 |
| GO:007149614 | Breast | IDC | cellular response to external stimulus | 45/1434 | 320/18723 | 5.40e-05 | 1.15e-03 | 45 |
| GO:003166814 | Breast | IDC | cellular response to extracellular stimulus | 35/1434 | 246/18723 | 2.79e-04 | 4.26e-03 | 35 |
| GO:000042212 | Breast | IDC | autophagy of mitochondrion | 15/1434 | 81/18723 | 1.13e-03 | 1.23e-02 | 15 |
| GO:006172612 | Breast | IDC | mitochondrion disassembly | 15/1434 | 81/18723 | 1.13e-03 | 1.23e-02 | 15 |
| GO:003166914 | Breast | IDC | cellular response to nutrient levels | 28/1434 | 215/18723 | 4.02e-03 | 3.25e-02 | 28 |
| GO:190300812 | Breast | IDC | organelle disassembly | 17/1434 | 114/18723 | 5.99e-03 | 4.31e-02 | 17 |
| GO:007149623 | Breast | DCIS | cellular response to external stimulus | 45/1390 | 320/18723 | 2.55e-05 | 5.87e-04 | 45 |
| GO:003166723 | Breast | DCIS | response to nutrient levels | 58/1390 | 474/18723 | 1.16e-04 | 2.03e-03 | 58 |
| GO:003166822 | Breast | DCIS | cellular response to extracellular stimulus | 35/1390 | 246/18723 | 1.54e-04 | 2.59e-03 | 35 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR45 | SNV | Missense_Mutation | novel | c.890N>T | p.Ser297Ile | p.S297I | Q9Y484 | protein_coding | deleterious(0) | possibly_damaging(0.841) | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
| WDR45 | SNV | Missense_Mutation | rs782703693 | c.808N>C | p.Thr270Pro | p.T270P | Q9Y484 | protein_coding | tolerated(0.44) | benign(0.042) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
| WDR45 | SNV | Missense_Mutation | c.1022N>G | p.Asp341Gly | p.D341G | Q9Y484 | protein_coding | tolerated(0.08) | possibly_damaging(0.841) | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| WDR45 | SNV | Missense_Mutation | rs782703693 | c.808A>C | p.Thr270Pro | p.T270P | Q9Y484 | protein_coding | tolerated(0.44) | benign(0.042) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| WDR45 | insertion | Nonsense_Mutation | novel | c.878_879insATAAAAGGCCCTTAATGGCATTTACGGCTTGAC | p.Asp293delinsGluTerLysAlaLeuAsnGlyIleTyrGlyLeuThr | p.D293delinsE*KALNGIYGLT | Q9Y484 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| WDR45 | SNV | Missense_Mutation | rs192312429 | c.527N>T | p.Ala176Val | p.A176V | Q9Y484 | protein_coding | deleterious(0.05) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR45 | SNV | Missense_Mutation | rs782395953 | c.335G>A | p.Arg112His | p.R112H | Q9Y484 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR45 | SNV | Missense_Mutation | c.1069N>A | p.Asp357Asn | p.D357N | Q9Y484 | protein_coding | tolerated(0.08) | possibly_damaging(0.662) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| WDR45 | SNV | Missense_Mutation | c.930C>G | p.Ile310Met | p.I310M | Q9Y484 | protein_coding | deleterious(0.05) | benign(0.169) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| WDR45 | SNV | Missense_Mutation | c.1078N>A | p.Asp360Asn | p.D360N | Q9Y484 | protein_coding | tolerated(0.07) | benign(0.042) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |